Molecular analysis of Kras and Nras mutations in a series of 720 patients for guiding the treatment of metastatic colorectal cancer in Turkey.

作者
H. Karadayi,Cigdem Aktas,İsmail Mert Alkaç,Y.H. Ozon,Hakan Berkil
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:34 (15_suppl): e13115-e13115 被引量:2
标识
DOI:10.1200/jco.2016.34.15_suppl.e13115
摘要

e13115 Background: Mutations in Kras and Nras genes in primary colorectal tumors are the reasons for nonresponse to anti-epidermal growth factor receptor (EGFR) antibodies in patients with metastatic colorectal cancer (mCRC). Results of the molecular analysis guides the treatment decision-making in mCRC. The aim of this study was to evaluate the Kras and Nras mutation data from 720 patients with mCRC between 01 January 2015 and 31 January 2016 using minisequencing method. Methods: We performed a two round nested PCR for the amplification of Exons 1, 2, 3 of Kras and Nras genes harbouring codons 12, 13, 59, 61, 117, and 146 followed by a multiplex minisequencing reaction for the detection of potential mutations. Results: A total of 720 patients were analysed for the mutations in codons 12, 13, 59, 61, 117, and 146 of Kras and Nras genes. Results were obtained from 718 out of 720 (99,72%) patients and no results were obtained from 2 (0,28%) of the cases. 400/718 (55,71%) patients were wild-type for Kras mutations while 318 of them carried a Kras mutation (44,29%). 8 of 318 (2,52%) patients carried two mutations which made totally 326 Kras mutations. Kras mutation rates were 192/326 (58,90%), 98/326 (30,06%), 3/326 (0,92%), 8/326 (2,45%), 3/326 (0,92%), 22/326 (6,75%) in codons 12, 13, 59, 61, 117, 146 respectively. Additional Nras mutation testing was performed for 400 patients which were found to be wild-type for Kras mutations. 31/400 (7,75%) patients were found to carry Nras mutations while 369 (92,25%) of them were wild-type for Nras mutations. 1 of 31 (3,23%) patients carried two mutations which made totally 32 Nras mutations. Mutation distribution was 10/32 (31,25%), 4/32 (12,50%), 4/32 (12,50%), 11/32 (34,38%), 2/32 (6,25%), 1/32 (3,13%) in codons 12, 13, 59, 61, 117, 146 respectively. Conclusions: High rate (349/718, 48,61%) of mutation finding in Kras and Nras testing makes mutation profiling in Kras and Nras genes an effective approach to select patients who are more likely to respond to anti-EGFR immunotherapy or rule out this treatment for those who are not likely to respond, and predict patient outcomes using minisequencing reaction which is a highly sensitive and cost effective method.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Akim应助霸气侧漏采纳,获得80
刚刚
终生科研徒刑完成签到 ,获得积分10
1秒前
Septvirouo9发布了新的文献求助10
1秒前
4秒前
大吉大利完成签到,获得积分10
4秒前
5秒前
5秒前
灵剑山完成签到 ,获得积分10
6秒前
领导范儿应助失眠健柏采纳,获得10
11秒前
11秒前
YYY完成签到 ,获得积分10
12秒前
栖风完成签到,获得积分10
12秒前
13秒前
123完成签到,获得积分10
16秒前
16秒前
水滇发布了新的文献求助10
17秒前
17秒前
Septvirouo9完成签到,获得积分10
18秒前
yuci完成签到,获得积分10
20秒前
yunwu完成签到,获得积分10
21秒前
贾克斯完成签到,获得积分10
21秒前
21秒前
23秒前
大模型应助yk采纳,获得10
23秒前
可靠连虎发布了新的文献求助10
24秒前
亚珍发布了新的文献求助10
25秒前
TONONO发布了新的文献求助10
28秒前
30秒前
chencf完成签到 ,获得积分10
32秒前
suli关注了科研通微信公众号
33秒前
111完成签到,获得积分10
34秒前
34秒前
bandian完成签到,获得积分10
34秒前
36秒前
37秒前
丰富语蕊应助研友_8oBM7Z采纳,获得20
37秒前
7yin秦发布了新的文献求助10
38秒前
orixero应助魔幻的可乐采纳,获得10
40秒前
40秒前
shuohua发布了新的文献求助10
40秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
An Introduction to Foreign Language Learning and Teaching 750
China Pluperfect I: Epistemology of Past and Outside in Chinese Art 520
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
Cosmos as Art Object: Studies in Plato's Timaeus and Other Dialogues 500
What is the Future of Psychotherapy in Digital Age? Technology, AI Bots, and Psychotherapy after Covid 444
煤炭地下气化渗流燃烧方法的研究 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7632493
求助须知:如何正确求助?哪些是违规求助? 9206895
关于积分的说明 19746124
捐赠科研通 7201852
什么是DOI,文献DOI怎么找? 3274853
关于科研通互助平台的介绍 2436742
邀请新用户注册赠送积分活动 2271539